People: Life Technologies Corp (LIFE.O)

Summary

Name	Age	Since	Current Position
Gregory Lucier	48	2004	Chairman of the Board, Chief Executive Officer
Mark Stevenson	50	2008	President, Chief Operating Officer
David Hoffmeister	58	2004	Chief Financial Officer
Ronnie Andrews	53	2012	President - Medical Sciences
Peter Leddy	49	2008	Senior Vice President - Global Human Resources and Internal Communications
Kelli Richard	44	2007	Vice President - Finance, Chief Accounting Officer
John Cottingham	58	2008	Chief Legal Officer, Secretary
George Adam	66	2008	Independent Director
Raymond Dittamore	69	2001	Independent Director
Donald Grimm	71	1998	Independent Director
Balakrishnan Iyer	56	2006	Independent Director
Ronald Matricaria	70	2004	Independent Director
Ora Pescovitz	56	2011	Independent Director
Per Peterson	68	2007	Independent Director
David U'Prichard	64	2004	Independent Director

» Insider Trading

Biographies

Name	Description
Gregory Lucier	Mr. Gregory T. Lucier (Greg) is Chairman of the Board, Chief Executive Officer of Life Technologies Corp. He is a global biotechnology company with a presence in more than 180 countries. Ranked 9th among the world’s 50 most innovative companies, Life Technologies, in products and services that accelerate advancements in basic research and drug development, molecular diagnostics, 21st century forensics, regenerative science and agricultural research. Mr. Lucier fosters a culture of excellence and applies his more than 25 years of strategic management at Life Technologies in his endeavor to shape an era of personalized medicine in which researchers can efficiently read, write and edit DNA for humanity’s benefit. Mr. Lucier previously served as a corporate officer at GE Healthcare and on the Board of the Sanford Burnham Institute, and currently serves on the Board of Directors at Synthetic Genomics, Inc., CareFusion Corporation, Rady Children’s Hospital and the California Healthcare Institute. He received his B.S. in Engineering from Pennsylvania State University and an M.B.A. from Harvard Business School.
Mark Stevenson	Mr. Mark P. Stevenson is President, Chief Operating Officer of Life Technologies Corp. From December 2007 to November 2008, Mr. Stevenson served as President and Chief Operating Officer of Life Technologies’ predecessor entity, Applied Biosystems. Mr. Stevenson joined Applied Biosystems in Europe in 1998, and held roles of increasing responsibility in Europe and Japan. Mr. Stevenson moved to the U.S. in 2004 to establish the Applied Markets Division of Applied Biosystems and, in 2006, was named President of the Molecular and Cellular Biology Division of Applied Biosystems. Mr. Stevenson has more than twenty (20) years of sales, marketing, and international executive management experience and received his B.S. in Chemistry from the University of Reading, UK, and an M.B.A. from Henley Management School, UK. Mr. Stevenson serves on the Board of Trustees of the Keck Graduate Institute and is an Executive Committee Board Member of BIOCOM, a life science association representing approximately 550 member companies is Southern California.
David Hoffmeister	Mr. David F. Hoffmeister is Chief Financial Officer of Life Technologies Corp. From October 2004 to November 2008, Mr. Hoffmeister served as Chief Financial Officer and Senior Vice President of Life Technologies’ predecessor entity, Invitrogen Corporation. Prior to joining Invitrogen Corporation, Mr. Hoffmeister held various positions over the course of twenty (20) years with McKinsey & Company, most recently as a senior partner serving clients in the healthcare, private equity and chemicals industries. Prior to joining McKinsey & Company, Mr. Hoffmeister held financial positions at GTE and W.R.Grace. Mr. Hoffmeister is a member of the board of Celanese Corporation. Mr. Hoffmeister received his B.S. in Business from the University of Minnesota and an M.B.A. from the University of Chicago.
Ronnie Andrews	Mr. Ronnie A. Andrews is President - Medical Sciences of Life Technologies Corp., since February 02, 2012. From 2010 – 2012, Mr. Andrews served as Chief Executive Officer for the Clarient Business Unit, and Segment Leader in Molecular Diagnostics, for GE Healthcare. From 2004 until GE’s acquisition of the company, he served as Chief Executive Officer and Vice Chairman of Clarient Healthcare. Prior to joining Clarient, Mr. Andrews served in a variety of leadership roles at Roche Molecular Diagnostics, Immucor and Abbott Diagnostics. He received his B.S. in Biology and Chemistry from Wofford College.
Peter Leddy	Dr. Peter Michael Leddy, Ph.D., is Senior Vice President - Global Human Resources and Internal Communications of Life Technologies Corp. From July 2005 to November 2008, Dr. Leddy served as Senior Vice President of Global Human Resources of Life Technologies’ predecessor entity, Invitrogen Corporation. Prior to joining Invitrogen Corporation, Dr. Leddy held several senior management positions with Dell Incorporated from 2000 to 2005. Prior to joining Dell Incorporated, Dr. Leddy served as the Executive Vice President of Human Resources at Promus Hotel Corporation. Dr. Leddy also served in a variety of executive and human resource positions at PepsiCo. Dr. Leddy received his B.A. in Psychology from Creighton University and his M.S. and Ph.D. in Industrial/Organizational Psychology from the Illinois Institute of Technology. Dr. Leddy is director of NuVasive, Inc., and a member of the California State University Professional Science Master’s Executive Board of Directors and is a former board member of the Biotechnology Institute.
Kelli Richard	Ms. Kelli A. Richard is Vice President - Finance, Chief Accounting Officer of Life Technologies Corp. Ms. Richard served as Vice President of Finance and Chief Accounting Officer of Life Technologies’ predecessor entity, Invitrogen Corporation. Ms. Richard joined Invitrogen Corporation in August 2005 with more than fourteen (14) years of accounting and financial reporting experience, previously serving as Vice President of Accounting and Reporting. Prior to joining Invitrogen Corporation, Ms. Richard held the position of Principal Accounting Officer at Gateway, Inc. Ms. Richard is a certified public accountant with a Bachelor of Business Administration degree from the University of Iowa.
John Cottingham	Mr. John A. Cottingham is Chief Legal Officer, Secretary of Life Technologies Corp. From May 2004 to November 2008, Mr. Cottingham served as Senior Vice President, General Counsel and Secretary of Life Technologies’ predecessor entity, Invitrogen Corporation. Mr. Cottingham served as Vice President, General Counsel of Invitrogen Corporation from September 2000 to May 2004. Prior to the merger of the former Life Technologies, Inc., or “LTI”, with Invitrogen Corporation in September 2000, Mr. Cottingham was the General Counsel and Assistant Secretary of LTI from January 1996 to September 2000. From May 1988 to December 1995, Mr. Cottingham served as an international corporate attorney with the Washington, D.C. office of Fulbright and Jaworski L.L.P. Mr. Cottingham received his B.S. in Political Science from Furman University, his J.D. from the University of South Carolina, his L.L.M. in Securities Regulation from Georgetown University and his M.S.E.L. from the University of San Diego.
George Adam	Mr. George F. Adam, Jr., is Independent Director of Life Technologies Corp., since November 21, 2008. Mr. Adam previously served on the Board of Applied Biosystems, and is the Chairman and Chief Executive Officer of Recondo Technology, Inc., a private healthcare software development company that he founded in 2007. Mr. Adam founded Adam Aircraft Industries, Inc., a designer and manufacturer of advanced aircraft, and New Era of Networks, Inc., an e-business infrastructure provider that went public in 1997 and filed for Chapter 7 bankruptcy proceedings on February 15, 2008. Mr. Adam previously served as a general partner at Goldman Sachs & Co. Before Goldman Sachs, Mr. Adam held executive positions at Baxter Healthcare, FMC, Litton Industries, and IBM. Mr. Adam also previously served on the Board of Directors for TransUnion, Inc. Mr. Adam received his B.S. in Engineering from the United States Military Academy at West Point and an M.B.A. from Golden Gate University.
Raymond Dittamore	Mr. Raymond V. Dittamore (Ray) serve as Independent Director of Life Technologies Corp., since July 26, 2001. Mr. Dittamore also serves as a director of QUALCOMM Incorporated and was formerly a member of the Board of Directors of Gen-Probe Incorporated and Digirad Corporation. In June 2001, Mr. Dittamore retired as a partner of Ernst & Young after thirty-five (35) years of service. Mr. Dittamore brings over three decades of public accounting experience to the Board of Directors, primarily serving companies in the life sciences industry. Mr. Dittamore received his B.S. from San Diego State University.
Donald Grimm	Mr. Donald W. Grimm serves as Independent Director of Life Technologies Corp., since June 1998. Mr. Grimm has been a director of Hamilton BioVentures, LLC since August 2001. Since June 1995, Mr. Grimm has served as Chairman and President of Strategic Design, LLC, a strategic planning and consulting company. Mr. Grimm retired from Eli Lilly & Company, a research-based pharmaceutical company, in December 1993 after twenty-three (23) years of service. Mr. Grimm held positions at Eli Lilly as Director of Worldwide Pharmaceutical Pricing, Director of Pharmaceutical Market Research and Director of Sales. Following these assignments, Mr. Grimm was President and CEO of Hybritech, Inc., a wholly owned subsidiary of Lilly. In addition, Mr. Grimm is currently a director of several private companies. Mr. Grimm received his B.S. in Pharmacy and his M.B.A. from the University of Pittsburgh.
Balakrishnan Iyer	Mr. Balakrishnan S. Iyer serves as Independent Director of Life Technologies Corp. Mr. Iyer is currently a Director of Skyworks Solutions, Inc., Power Integrations, Inc., IHS Inc., and Qlogic Corporation. From October 1998 to June 2003, he was Senior Vice President and Chief Financial Officer of Conexant Systems, Inc. Mr. Iyer previously served as Senior Vice President and Chief Financial Officer of VLSI Technology, Inc., where he was responsible for all worldwide financial functions, information technology and strategic planning. During his career, he has held a variety of other key management positions, including Finance Director and Group Controller for a $1 billion business at Advanced Micro Devices. Mr. Iyer received his B.S. in Mechanical Engineering from the Indian Institute of Technology, Madras and his M.S. in Industrial Engineering from the University of California, Berkeley. Mr. Iyer also received an M.B.A. in Finance from the Wharton School of Business.
Ronald Matricaria	Mr. Ronald A. Matricaria serves as Independent Director of Life Technologies Corp., since July 22, 2004. Mr. Matricaria is the former Chairman and Chief Executive Officer of St. Jude Medical, Inc. Mr. Matricaria spent 23 years with Eli Lilly and Company, Inc., serving in several leadership roles. His last position was Executive Vice President of the Pharmaceutical Division of Eli Lilly and Company and President of its North American operations. He also served as President of Eli Lilly International Corporation. In 2002, he was recognized by the medical device industry with a lifetime achievement award. In addition, Mr. Matricaria is Chairman of the Board of Volcano Therapeutics, Inc., is a member of the board of directors of Phoenix Children’s Hospital, and is Trustee Emeritus of the University of Minnesota Foundation. Mr. Matricaria holds a B.S. from the Massachusetts College of Pharmacy and was awarded an Honorary Doctorate degree in Pharmacy in recognition of his contributions to the practice of pharmacy.
Ora Pescovitz	Dr. Ora H. Pescovitz, M.D., serves as Independent Director of Life Technologies Corp., since April 29, 2011. On May 11, 2009, Dr. Pescovitz became the University of Michigan’s first female Executive Vice President for Medical Affairs and Health System Chief Executive Officer. Prior to taking the University of Michigan post, Dr. Pescovitz had an career serving as Executive Associate Dean for Research Affairs at Indiana University School of Medicine from 2000-2009, President and CEO of Riley Hospital for Children in Indianapolis from 2004-2009 and interim Vice President for Research Administration at Indiana University from 2007-2009. Dr. Pescovitz is a nationally recognized pediatric endocrinologist and researcher who has published 180 papers and books, and received numerous awards for her research and teaching. Most recently, the Endocrine Society named her the 2011 recipient of its prestigious Robert H. Williams Distinguished Leadership Award for her exceptional contributions to endocrinology through her leadership, teaching and research and her mentorship of trainees and associates. Dr. Pescovitz has served as President of the Society for Pediatric Research, the nation’s pediatric research organization, President of the Lawson Wilkins (North American) Pediatric Endocrine Society, chair of the March of Dimes Grants Review Committee, and a member of the Ad-Hoc Group for Medical Research Funding, the board of the Hormone Foundation, the board of the National Association of Children’s Hospitals and Related Institutions (NACHRI), and is currently on the board of the Children’s Miracle Network. Dr Pescovitz received her B.M.Sc. in the Honors Program in Medical Education at Northwestern University and her M.D. at Northwestern University Medical School.
Per Peterson	Dr. Per A. Peterson, M.D., Ph.D., serves as Independent Director of Life Technologies Corp., since March 2007. Dr. Peterson recently retired as Chairman, Research & Development, Pharmaceuticals at Johnson & Johnson. Dr. Peterson joined Johnson & Johnson in 1994 as Vice President, Drug Discovery, of the R.W. Johnson Pharmaceutical Research Institute. Dr. Peterson is also a Director for Entelos, Inc., a life sciences company focused on improving human health through predictive biosimulation, which he joined in 2007 and Bio Investment Group, each of which are privately held companies. Dr. Peterson was named Group Vice President of the Pharmaceutical Research Institute in April 1998 and its President in November 1998. In 2000, Dr. Peterson was named Chairman, Research & Development, Pharmaceuticals Group and became a member of the Executive Committee in 2001. Prior to joining Johnson & Johnson, Dr. Peterson spent eight (8) years at Scripps Research Institute in La Jolla, CA, where he headed the Division of Molecular Immunogenetics before being appointed Chairman of the Department of Immunology in 1987. Dr. Peterson had earlier served as Director of the Wallenberg Laboratory, as well as Professor of Cell Biology at the University of Uppsala, Sweden. Dr. Peterson received his B.M. in Medicine and his Ph.D. in Medicinal Biochemistry from the University of Uppsala, Sweden.
David U'Prichard	Dr. David C. U'Prichard, Ph.D., serves as Independent Director of Life Technologies Corp., since April 2004. Dr. U’Prichard currently serves as Chief Scientific Officer of BioMotiv LLC, the for-profit arm of the Harrington Project for Discovery and Development. From September 1999 to April 2003 he served as CEO of 3-Dimensional Pharmaceuticals, Inc. Dr. U’Prichard served as Chairman of Research and Development at SmithKline Beecham from July 1997 to March 1999. He served in senior R&D management positions at ICI/Zeneca from July 1986 to June 1997. Dr. U’Prichard has served as an Associate Professor of Pharmacology and Neurobiology at Northwestern University Medical School and has held academic appointments at The John Hopkins University, and the Universities of Maryland and Pennsylvania. He is an honorary Professor at the University of Glasgow. Dr. U’Prichard serves as Chairman of the Board of Cyclacel Pharmaceuticals Inc. (Berkeley Heights, NJ) and is a Director of Iroko Pharmaceuticals (Philadelphia, PA), Naurex, Inc. (Chicago, IL) and Angstrom Pharmaceuticals (San Diego, CA). Dr. U’Prichard received his B.S. in Pharmacology from the University of Glasgow and a Ph.D. in Pharmacology from the University of Kansas.

Basic Compensation

Name	Fiscal Year Total
Gregory Lucier	10,268,400
Mark Stevenson	5,295,160
David Hoffmeister	2,676,640
Ronnie Andrews	3,947,190
Peter Leddy	1,887,930
Kelli Richard	--
John Cottingham	2,099,470
George Adam	--
Raymond Dittamore	--
Donald Grimm	--
Balakrishnan Iyer	--
Ronald Matricaria	--
Ora Pescovitz	--
Per Peterson	--
David U'Prichard	--

As Of 30 Dec 2012

Options Compensation

Name	Options	Value
Gregory Lucier	1,354,852	27,395,696
Mark Stevenson	0	0
David Hoffmeister	422,728	6,212,580
Ronnie Andrews	0	0
Peter Leddy	0	0
Kelli Richard	0	0
John Cottingham	189,199	11,744,815
George Adam	0	0
Raymond Dittamore	0	0
Donald Grimm	0	0
Balakrishnan Iyer	0	0
Ronald Matricaria	0	0
Ora Pescovitz	0	0
Per Peterson	0	0
David U'Prichard	0	0

Insider Trading

Name	Shares Traded	Price
IYER BALAKRISHNAN S	4,888	$0.00
UPRICHARD DAVID C	4,888	$0.00
LEVINE ARNOLD J	4,892	$0.00
LEVINE ARNOLD J	4,021	$0.00
LORIMIER BRADLEY G	4,052	$0.00
LEVINE ARNOLD J	6,033	$0.00
LORIMIER BRADLEY G	6,033	$0.00
LORIMIER BRADLEY G	2,000	$0.00
LEVINE ARNOLD J	1,013	$0.00
LORIMIER BRADLEY G	5,228	$0.00
LEVINE ARNOLD J	3,473	$0.00
LORIMIER BRADLEY G	2,000	$0.00
LORIMIER BRADLEY G	3,742	$0.00
LORIMIER BRADLEY G	4,888	$0.00
LORIMIER BRADLEY G	4,021	$0.00
LEVINE ARNOLD J	1,222	$0.00
RICHARD KELLI	577	$65.75
LEDDY PETER MICHAEL	3,067	$0.00
COTTINGHAM JOHN A	3,067	$0.00
LUCIER GREGORY T	12,003	$65.75
ANDREWS RONALD ASBURY	3,067	$0.00
HOFFMEISTER DAVID F	2,668	$65.75
STEVENSON MARK P	10,479	$0.00
LEDDY PETER MICHAEL	1,601	$65.75
ANDREWS RONALD ASBURY	1,213	$65.75

» Full list on Insider Trading

People: Life Technologies Corp (LIFE.O)

Related Topics:

Summary

Biographies

Basic Compensation

Options Compensation

Related Topics: